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)hapter 8
iummary, discussion' and conclusions
3.1 Summary
Ihis thesis focuses on tlvo asPects of human pulmonary 
emphysema' The first part






(.h"pt. ,i s-l) deals with the effects of corticosteroid
treatment in emPhYsema'
The study population of this thesis consisted of a group 
of 5.8 male non-allergic pa-
tients with copD *J".r-t."ldiagnosis of .-pilyr.-a. 
All patients were smokers
o. .*-r-ok.rs. All had normal alphat-antitrypsin serum 
levels'
The pathogenesis of emphysema is largely unknown' 
Chronic inflammation of the
pe r i phe ra la i rways i , . hough , top lay "n i -po , . " . , t r o l e .Fo rmanyyea rs ' i t hasbeen
hypothesized that an i-bal",,.. between proteolytic, 
especially elastolytic, and anti-
proteolyt icact iv i ry i t "nt t t " 'g 'under l iesthedestruct iu t th" t 'g t t thatarefoundin
the pulmonary p"r.rr.if-" in".-phyr.-a. In patients 
with normal alpha,-antitryp-
sin serum levels, the c"us. of this imb"lan.e h", .rot 
yet been elucidated' The maior
risk factor fo..-phy..L is cigarette smoking. since 
only about 15olo of smokers
develop copD, however, it h"s to b. p..s,rri.d that 
other factors in addition to
smokingcontr ibutetotheproposedprotease.ant iproteaseimbalanceandthedevel-
opment of emPhYsema'
Inorder to invest igatethepresenceandnatureof inf lammatoryprocessesinthepe-
ripheral airways of p"tietttt with emphysema' we performed 
bronchoalveolar lavage
(BAL) in patients *i,n .-prryr.-" 
".,i 
healthy.ontrol, (chapter 2). BAL appeared
tobeasafeandwel l - to leratedprocedurei , 'p" t i . , , t ,as.wel lasco.nt ro ls .Recoveryof
BALf lu idandcel lswashigher incontro ls t .h" , ' i , 'pat ients.Di f ferent ia lce l lcounts
were not significantly diffei-ent in controls and patients. 
Patients underwent a second
BAL after ,r.",In.rr,'*irh a short course of orj prednisolone. Tieatment 
with pred-
nisolonedidnot inducemajorchangesinBALf i r rd ingr .Takentogether ' theseresul ts
are not suggestive of 
"" 
*ttit" inflammatory Process in the peripheral airways 
of pa-
tients with emPhYsema'
In contrast, i.r.r."rJr,rmbers of cells and significant 
differences in differential cell
counrs were found in ,nlot .^ as compared to".*-r-ok.rs. 
This was observed in both
r07
controls and patients, reflecting an increased inflammatory burden in the lungs of
smoking subjects. This finding does not explain, however, why some smokers devel-
op emphysema whereas others do not.
Polymorphonuclear leukocytes (PMN) are the major human source of elastase. In
addition, these cells can produce reactive oxygen metabolites that have been shown
to be capable of inactivating antiproteases. The studies described in the chapters 3
and 4 are based on the hypothesis that an increased "activity'', i.e. an increased ten-
dency to release lysosomal enzymes and/or to generate reactive oxygen species, of
PMN might underlie the proposed protease-antiprotease imbalance in emphysema
and the increased susceptibiliry of some smokers to develop emphysema. Poly-
morphonuclear leukocytes (PMN) were isolated from peripheral blood of patients
with emphysema and healthy controls. Neither the in vitro release of elastase, B-glu-
curonidase, and myeloperoxidase, nor the total cellular content of these lysosomal
enzymes was significantly different in patients with emphysema and healthy sub-
jects. 'Within both groups, no significant differences were found between smokers
and ex-smokers (chapter 3). On the basis of these results it is unlikely that an abnor-
maliry in PMN lysosomal enzyme release or content is a pathogenetic factor in em-
physema. Our results, however, do not exclude the possibility that PMN behave dif-
ferently in the local environment of the lungs.
In contrast to lysosomal enzyme release, the in vitro generation of superoxide anion
(O, ) bf PMN was significantly higher in patients with emphysema than in healthy
controls. Moreover, the increased in vitro generation of Or- in the patient group sig-
nificantly decreased after in vivo trearment with oral prednisolone (chapter 4). The-
se observations suggest an abnormality in the oxidative metabolism of PMN that
may predispose an individual for the development of emphysema, since an increased
oxidative metabolism may disturbe the protease-antiprotease balance through oxida-
tive inactivation of antiproteases. This abnormality may at least partially be reversed
by treatment with corticosteroids. In patients as well as controls, Or- generation by
PMN was not significantly different between smoking and ex-smoking individuals,
indicating that the observed abnormaliry in Or- generation is not related to actual
smoking habits.
Chapter 5 gives an overview of the effects of treatment with corticosteroids that ha-
ve been reported in COPD. Short-term studies with oral as well as inhaled cortico-
steroids show little or no benefit. Long-term studies are scarce and their interpreta-
tion is hampered by methodological problems (retrospective studies) and patient se-
lection (inclusion of allergic individuals or patients with rapidly deteriorating lung
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ture of emphysema and the possibiliry that treatment effects manifbst themselves on-
ly after prolonged treatment periods.
To determine the effectiveness of corticosteroids in emphysema, we performed a
long-term, randomized, double-blind, placebo-controlled, parallel intervention stu-
dy in our group of non-allergic emphysema patients. Patients were treated with ei-
ther
1) inhaled budesonide 1600 pg per day plus placebo tablet, or
2) inhaled budesonide 1600 pg per day plus oral prednisolone 5 mg per day, or
3) placebo inhalations plus placebo tablet.
Treatment was given during two years. In that period, clinical assessment, consisting
of history, physical examination, and spirometry, took place every two months. PC20
histamine was measured every four months.
In chapter 6, the effects of corticosteroid treatment on withdrawal from the study,
pulmonary symptoms, lung function decline, and frequency and duration of exacer-
bations are described.
Withdrawal due to pulmonary problems, such as frequent exacerbations or rapid de-
terioration of lung function, was significantly higher in the placebo group than in
the actively treated groups, suggesting a favourable influence of corticosteroids on
pulmonary "stability' in patients with emphysema. teatment with corticosteroids
significantly reduced pulmonary symptoms. Median annual decline of FEV, was
smaller in both actively treated groups (-30 ml/yr in the budesonide group and -40
ml/yr in the budesonide plus prednisolone group, respectively) than in the placebo
group (-60 ml/yr), but variation was large and differences were not statistically sig-
nificant. No effect was found on frequency or duration of exacerbations in patients
who completed the whole study. Tieatment with an inhaled corticosteroid in combi-
nation with oral prednisolone was not more effective than treatment with an inhaled
corticosteroid alone. Finally, our observations reflected the deleterious eflect of
smoking: FEV, declined more rapidly in smokers than in ex-smokers, whether they
were treated with corticosteroids or not.
In chapter 7 we describe the effect of corticosteroid treatment on airways hyperres-
ponsiveness (AHR) in patients with emphysema. In this study we also investigated
which factors modulate level and longitudinal change in AHR in these patients.
During the rwo years of follow-up, PCro histamine decreased in the whole group,
and this decrease was not influenced by corticosteroid treatment. PCro tended to de-
crease faster in smokers than in ex-smokers. PCrn was significantly associated with
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prechallenge FEV, at each time point. This association has been found in other stud-
ies as well. 
'We 
observed, however, that not only prechallenge FEV, determines the
level and decline of AHR in patients with emphysema. Total serum IgE level at the
beginning of the study was significantly and inversely associated with PCr,, hista-
mine. Moreover, a higher initial serum IgE level was associated with a smaller annu-
al decrease of PCrn. No significant associations were found between the number of
blood eosinophils at the start of the study and level or decline of PCro. The observed
relationships berween serum IgE and level and decline of AHR are remarkable since
we included only non-allergic patients with serum IgE levels within rhe normal ran-
ge. Our findings suggest an important role for IgE, in the course of emphysema.
8.2 Discussion and implications for future research
The aim of the studies described in this thesis was:
- to improve the understanding of the pathogenesis of emphysema and especi:rlly of
the role of polymorphonuclear leukocytes in the proposed protease-anriprorease
imbalance;
- to determine the efficacy of long-term treatment with corticosteroids in emphysema.
To achieve this goal, we studied a group of carefully selected pi.rtients with COPD
and clinical manifestations of emphysema. Emphysema was diagnosed on the basis
of history, physical examination, lung function tests, and chest X-ray. Because em-
physema can be diagnosed with certainty only by means of pathologic-anatomical
examination of biopsy specimens, we had no definite proof of the presence and ex-
tent of emphysema in our patient population. In clinical practice, however, clinical
criteria are considered sufficient and it is no routine to confirm the diagnosis by
means of a biopsy, which requires an invasive procedure that can have potentially
dangerous complications. By the time we selected our parient population (in the
middle eighties) the value of compured tomography (CT) in diagnosing emphysema
had not yet been established. Nowadays, this technique may be of additional value in
assessing the presence and severity of emphysema during life, especially for research
purposes.
Our BAL findings (chapter 2) do not confirm the presence of an active inflammaro-
ry process in the peripheral airways of patients with emphysema. This is remarkable,
since a chronic inflammatory process is thought to be present in both developing
and established COPD. Several factors have to be considered when interpreting this
finding. Although BAL can be performed safely in patients with emphysema, rhe
